Sustained Rigors and Fever in Filgrastim HypersensitivitySustained Rigors and Fever in Filgrastim Hypersensitivity
Learn from this case study of a 36-year-old man who presented to an emergency room with fever, fatigue, and severe rectal pain. Oncology Nursing Forum (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2015 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news
Novartis Neupogen Biosimilar: On Sale Now
Novartis' Zarxio -- the first U.S. biosimilar drug -- is on sale for 15% less than the original drug, Amgen's blockbuster, Neupogen. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 3, 2015 Category: Pharmaceuticals Source Type: news
Sandoz launches Zarxio (TM) (filgrastim-sndz), the first biosimilar in the United States
Launch follows March 6, 2015 FDA approval. Sandoz One SourceTM offers patient support services (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 3, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Clinical trials Practical therapeutics Oncology fda approval filgrastim-sndz Latest News zarxio Source Type: news
Novartis Closer to Selling Copy of Amgen's Neupogen
A federal appeals court in Washington denied Amgen Inc.’s request for a temporary injunction to block Novartis AG from selling a copycat version of the blockbuster drug Neupogen in the U.S. (Source: WSJ.com: Health)
Source: WSJ.com: Health - September 2, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news
Neupogen (Filgrastim Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 14, 2015 Category: Drugs & Pharmacology Source Type: news
Novartis's Sandoz cleared to launch generic version of Amgen’s Neupogen
Novartis's subsidiary Sandoz has been cleared to launch its biosimilar Zarxio (filgrastim) in September, after the US Court of Appeals for the Federal Circuit declined Amgen's claims. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 21, 2015 Category: Pharmaceuticals Source Type: news
Novartis Blocked From Selling Neupogen Copycat Until Sept. 2Novartis Blocked From Selling Neupogen Copycat Until Sept. 2
Novartis AG unit Sandoz must wait until Sept. 2 to sell Zarxio (filgrastim-sndz), the first biosimilar drug to be approved in the United States and a copycat version of Amgen Inc's $1.2 billion-a-year anti-infection drug Neupogen (filgrastim), a U.S. appeals court said on Tuesday. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 21, 2015 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news
Drugmaker Novartis blocked from selling Neupogen copycat until Sept 2
NEW YORK (Reuters) - Novartis AG must wait until Sept. 2 to sell the first biosimilar drug to be approved in the United States, a copycat version of Amgen Inc's $1.2 billion-a-year Neupogen, a U.S. appeals court said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - July 21, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis Keeps Fighting for Neupogen Biosimilar
Novartis' Sandoz unit asked an appeals court to lift a preliminary injunction barring it from selling its biosimilar Zarxio, a cheaper version of Amgen's cancer blockbuster. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 4, 2015 Category: Pharmaceuticals Source Type: news
Novartis tries to get U.S. ban lifted on sale of Neupogen copycat
WASHINGTON (Reuters) - Novartis AG unit Sandoz asked a U.S. appeals court on Wednesday to lift a preliminary injunction barring it from selling its biosimilar Zarxio, a cheaper version of a drug that fends off infections in cancer patients. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Biosimilar Filgrastim vs Lenograstim in Autologous HSCTBiosimilar Filgrastim vs Lenograstim in Autologous HSCT
Find out how these biosimilars stack up for autologous HSCT in patients with hematological malignancies. Therapeutic Advances in Hematology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 2, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
New research leads to FDA approval of first drug to treat radiation sickness
New research has led to FDA approval of the use of a drug to treat the effects of radiation exposure following a nuclear incident. The drug, Neupogen, is the first ever approved for the treatment of acute radiation injury. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 22, 2015 Category: Science Source Type: news
New research leads to FDA approval of first drug to treat radiation sickness
(University of Maryland School of Medicine) New research has led the FDA to approve use of a drug to treat the effects of radiation exposure following a nuclear incident. The drug, Neupogen, is the first ever approved for the treatment of acute radiation injury. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 22, 2015 Category: Global & Universal Source Type: news
Novartis 'biosimilar' drug blocked by U.S. appeals court
(Reuters) - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients. (Source: Reuters: Health)
Source: Reuters: Health - May 7, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
Monthly News Roundup - March 2015
FDA Approves First Biosimilar Product Zarxio
On Friday, March 6th the U.S. Food and Drug Administration (FDA) approved Sandoz’s Zarxio (filgrastim-sndz), the first U.S. approved biosimilar. Zarxio, the biosimilar for Amgen’s filgrastim... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2015 Category: Pharmaceuticals Source Type: news
